nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—DRD5—attention deficit hyperactivity disorder	0.301	0.372	CbGaD
L-DOPA—DRD4—attention deficit hyperactivity disorder	0.154	0.19	CbGaD
L-DOPA—DRD3—attention deficit hyperactivity disorder	0.133	0.164	CbGaD
L-DOPA—DRD1—attention deficit hyperactivity disorder	0.13	0.161	CbGaD
L-DOPA—DRD2—attention deficit hyperactivity disorder	0.092	0.113	CbGaD
L-DOPA—PSIP1—forebrain—attention deficit hyperactivity disorder	0.00319	0.0646	CbGeAlD
L-DOPA—PSIP1—cardiovascular system—attention deficit hyperactivity disorder	0.00269	0.0546	CbGeAlD
L-DOPA—PSIP1—midbrain—attention deficit hyperactivity disorder	0.0021	0.0427	CbGeAlD
L-DOPA—SLC7A8—forebrain—attention deficit hyperactivity disorder	0.0021	0.0426	CbGeAlD
L-DOPA—DDC—forebrain—attention deficit hyperactivity disorder	0.00182	0.0368	CbGeAlD
L-DOPA—DRD5—forebrain—attention deficit hyperactivity disorder	0.00175	0.0354	CbGeAlD
L-DOPA—PSIP1—nervous system—attention deficit hyperactivity disorder	0.00173	0.0351	CbGeAlD
L-DOPA—PSIP1—central nervous system—attention deficit hyperactivity disorder	0.00167	0.0338	CbGeAlD
L-DOPA—PSIP1—cerebellum—attention deficit hyperactivity disorder	0.00163	0.033	CbGeAlD
L-DOPA—L-Tryptophan—TPH2—attention deficit hyperactivity disorder	0.00157	0.241	CrCbGaD
L-DOPA—SLC7A5—cardiovascular system—attention deficit hyperactivity disorder	0.00138	0.0279	CbGeAlD
L-DOPA—DRD1—forebrain—attention deficit hyperactivity disorder	0.00134	0.0271	CbGeAlD
L-DOPA—PSIP1—brain—attention deficit hyperactivity disorder	0.00132	0.0268	CbGeAlD
L-DOPA—DDC—midbrain—attention deficit hyperactivity disorder	0.0012	0.0243	CbGeAlD
L-DOPA—SLC7A8—nervous system—attention deficit hyperactivity disorder	0.00114	0.0231	CbGeAlD
L-DOPA—DRD4—brain—attention deficit hyperactivity disorder	0.0011	0.0223	CbGeAlD
L-DOPA—SLC7A8—central nervous system—attention deficit hyperactivity disorder	0.0011	0.0222	CbGeAlD
L-DOPA—SLC7A5—midbrain—attention deficit hyperactivity disorder	0.00107	0.0218	CbGeAlD
L-DOPA—SLC7A8—cerebellum—attention deficit hyperactivity disorder	0.00107	0.0217	CbGeAlD
L-DOPA—DRD3—nervous system—attention deficit hyperactivity disorder	0.00101	0.0205	CbGeAlD
L-DOPA—DDC—nervous system—attention deficit hyperactivity disorder	0.000986	0.02	CbGeAlD
L-DOPA—DRD3—central nervous system—attention deficit hyperactivity disorder	0.000974	0.0198	CbGeAlD
L-DOPA—DDC—central nervous system—attention deficit hyperactivity disorder	0.00095	0.0193	CbGeAlD
L-DOPA—DRD5—nervous system—attention deficit hyperactivity disorder	0.000949	0.0192	CbGeAlD
L-DOPA—DRD5—central nervous system—attention deficit hyperactivity disorder	0.000913	0.0185	CbGeAlD
L-DOPA—SLC7A5—nervous system—attention deficit hyperactivity disorder	0.000883	0.0179	CbGeAlD
L-DOPA—DRD1—midbrain—attention deficit hyperactivity disorder	0.000882	0.0179	CbGeAlD
L-DOPA—SLC7A8—brain—attention deficit hyperactivity disorder	0.000871	0.0177	CbGeAlD
L-DOPA—SLC7A5—central nervous system—attention deficit hyperactivity disorder	0.000851	0.0172	CbGeAlD
L-DOPA—SLC7A5—cerebellum—attention deficit hyperactivity disorder	0.000831	0.0169	CbGeAlD
L-DOPA—DRD2—forebrain—attention deficit hyperactivity disorder	0.000789	0.016	CbGeAlD
L-DOPA—DRD3—brain—attention deficit hyperactivity disorder	0.000774	0.0157	CbGeAlD
L-DOPA—DDC—brain—attention deficit hyperactivity disorder	0.000754	0.0153	CbGeAlD
L-DOPA—DRD5—brain—attention deficit hyperactivity disorder	0.000725	0.0147	CbGeAlD
L-DOPA—DRD1—nervous system—attention deficit hyperactivity disorder	0.000725	0.0147	CbGeAlD
L-DOPA—DRD1—central nervous system—attention deficit hyperactivity disorder	0.000698	0.0141	CbGeAlD
L-DOPA—SLC7A5—brain—attention deficit hyperactivity disorder	0.000675	0.0137	CbGeAlD
L-DOPA—SLC16A10—cerebellum—attention deficit hyperactivity disorder	0.000637	0.0129	CbGeAlD
L-DOPA—Levonordefrin—ADRA2C—attention deficit hyperactivity disorder	0.000609	0.0936	CrCbGaD
L-DOPA—DRD1—brain—attention deficit hyperactivity disorder	0.000554	0.0112	CbGeAlD
L-DOPA—DRD2—midbrain—attention deficit hyperactivity disorder	0.000521	0.0106	CbGeAlD
L-DOPA—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000474	0.00961	CbGeAlD
L-DOPA—Methyldopa—COMT—attention deficit hyperactivity disorder	0.00046	0.0707	CrCbGaD
L-DOPA—Droxidopa—ADRA2C—attention deficit hyperactivity disorder	0.000429	0.0659	CrCbGaD
L-DOPA—DRD2—nervous system—attention deficit hyperactivity disorder	0.000428	0.00868	CbGeAlD
L-DOPA—DRD2—central nervous system—attention deficit hyperactivity disorder	0.000412	0.00836	CbGeAlD
L-DOPA—DRD2—cerebellum—attention deficit hyperactivity disorder	0.000403	0.00817	CbGeAlD
L-DOPA—Norepinephrine—ADRA2C—attention deficit hyperactivity disorder	0.000361	0.0555	CrCbGaD
L-DOPA—Dopamine—DRD5—attention deficit hyperactivity disorder	0.000356	0.0547	CrCbGaD
L-DOPA—Epinephrine—ADRA2C—attention deficit hyperactivity disorder	0.000328	0.0504	CrCbGaD
L-DOPA—DRD2—brain—attention deficit hyperactivity disorder	0.000327	0.00663	CbGeAlD
L-DOPA—Methyldopa—ADRA2A—attention deficit hyperactivity disorder	0.000293	0.0451	CrCbGaD
L-DOPA—Levonordefrin—ADRA2A—attention deficit hyperactivity disorder	0.00026	0.0399	CrCbGaD
L-DOPA—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000257	0.00522	CbGeAlD
L-DOPA—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000248	0.00502	CbGeAlD
L-DOPA—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000242	0.00491	CbGeAlD
L-DOPA—Dopamine—COMT—attention deficit hyperactivity disorder	0.000225	0.0345	CrCbGaD
L-DOPA—CYP2D6—brain—attention deficit hyperactivity disorder	0.000197	0.00399	CbGeAlD
L-DOPA—Droxidopa—ADRA2A—attention deficit hyperactivity disorder	0.000183	0.0281	CrCbGaD
L-DOPA—Dopamine—DRD4—attention deficit hyperactivity disorder	0.000182	0.028	CrCbGaD
L-DOPA—Dopamine—MAOA—attention deficit hyperactivity disorder	0.00017	0.026	CrCbGaD
L-DOPA—Dopamine—DRD3—attention deficit hyperactivity disorder	0.000157	0.0241	CrCbGaD
L-DOPA—Dopamine—DRD1—attention deficit hyperactivity disorder	0.000154	0.0237	CrCbGaD
L-DOPA—Norepinephrine—ADRA2A—attention deficit hyperactivity disorder	0.000154	0.0237	CrCbGaD
L-DOPA—Dopamine—SLC6A3—attention deficit hyperactivity disorder	0.000146	0.0225	CrCbGaD
L-DOPA—Epinephrine—ADRA2A—attention deficit hyperactivity disorder	0.00014	0.0215	CrCbGaD
L-DOPA—Norepinephrine—DRD2—attention deficit hyperactivity disorder	0.000117	0.018	CrCbGaD
L-DOPA—Dopamine—SLC6A4—attention deficit hyperactivity disorder	0.000109	0.0168	CrCbGaD
L-DOPA—Dopamine—DRD2—attention deficit hyperactivity disorder	0.000109	0.0167	CrCbGaD
L-DOPA—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	6.45e-05	0.000484	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.42e-05	0.000482	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	6.31e-05	0.000474	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	6.23e-05	0.000467	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	6.2e-05	0.000465	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ADRA2C—attention deficit hyperactivity disorder	6.13e-05	0.00046	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	6.09e-05	0.000457	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	6.07e-05	0.000455	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	6.02e-05	0.000452	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	6.01e-05	0.000451	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.01e-05	0.000451	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	6e-05	0.00045	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	5.98e-05	0.000449	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	5.95e-05	0.000446	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	5.94e-05	0.000446	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	5.92e-05	0.000444	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.91e-05	0.000443	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	5.89e-05	0.000442	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	5.82e-05	0.000437	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	5.79e-05	0.000434	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	5.71e-05	0.000429	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	5.68e-05	0.000426	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	5.64e-05	0.000423	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	5.62e-05	0.000422	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	5.61e-05	0.000421	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	5.54e-05	0.000416	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	5.53e-05	0.000415	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	5.46e-05	0.00041	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.43e-05	0.000408	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.41e-05	0.000406	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	5.37e-05	0.000403	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	5.3e-05	0.000398	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	5.24e-05	0.000393	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	5.24e-05	0.000393	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	5.2e-05	0.00039	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	5.17e-05	0.000388	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	5.15e-05	0.000387	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	5.1e-05	0.000383	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.1e-05	0.000383	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	5.09e-05	0.000382	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	5.03e-05	0.000378	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	4.99e-05	0.000375	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	4.93e-05	0.00037	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	4.92e-05	0.00037	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	4.89e-05	0.000367	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	4.83e-05	0.000363	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	4.82e-05	0.000362	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	4.81e-05	0.000361	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.74e-05	0.000356	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	4.72e-05	0.000354	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.69e-05	0.000352	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	4.68e-05	0.000351	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	4.65e-05	0.000349	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	4.64e-05	0.000348	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.63e-05	0.000348	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	4.6e-05	0.000345	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	4.58e-05	0.000344	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	4.58e-05	0.000344	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	4.58e-05	0.000344	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	4.54e-05	0.000341	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	4.53e-05	0.00034	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	4.53e-05	0.00034	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	4.52e-05	0.000339	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	4.52e-05	0.000339	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.5e-05	0.000338	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	4.47e-05	0.000336	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.46e-05	0.000335	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	4.44e-05	0.000333	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.43e-05	0.000333	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	4.38e-05	0.000329	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.36e-05	0.000327	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—EP300—attention deficit hyperactivity disorder	4.35e-05	0.000326	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.27e-05	0.00032	CbGpPWpGaD
L-DOPA—DDC—Metabolism—TPH2—attention deficit hyperactivity disorder	4.23e-05	0.000318	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.23e-05	0.000318	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.21e-05	0.000316	CbGpPWpGaD
L-DOPA—DDC—Metabolism—DPYD—attention deficit hyperactivity disorder	4.16e-05	0.000313	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.15e-05	0.000311	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.05e-05	0.000304	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.03e-05	0.000302	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.01e-05	0.000301	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	3.99e-05	0.0003	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	3.96e-05	0.000297	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.95e-05	0.000296	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	3.94e-05	0.000296	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	3.93e-05	0.000295	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.9e-05	0.000292	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	3.87e-05	0.000291	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.87e-05	0.000291	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.87e-05	0.000291	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—EP300—attention deficit hyperactivity disorder	3.79e-05	0.000285	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	3.77e-05	0.000283	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.77e-05	0.000283	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.76e-05	0.000282	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	3.69e-05	0.000277	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	3.68e-05	0.000276	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.65e-05	0.000274	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.63e-05	0.000272	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.58e-05	0.000269	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	3.56e-05	0.000267	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.54e-05	0.000266	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	3.5e-05	0.000263	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.46e-05	0.00026	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	3.46e-05	0.00026	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	3.46e-05	0.00026	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	3.45e-05	0.000259	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	3.42e-05	0.000257	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	3.42e-05	0.000257	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.42e-05	0.000257	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	3.4e-05	0.000255	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.39e-05	0.000254	CbGpPWpGaD
L-DOPA—DDC—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.38e-05	0.000254	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	3.35e-05	0.000252	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.34e-05	0.000251	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.32e-05	0.000249	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.3e-05	0.000247	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	3.29e-05	0.000247	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.29e-05	0.000247	CbGpPWpGaD
L-DOPA—PSIP1—Disease—EP300—attention deficit hyperactivity disorder	3.23e-05	0.000242	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.22e-05	0.000242	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.12e-05	0.000234	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.08e-05	0.000231	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.08e-05	0.000231	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.06e-05	0.00023	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.04e-05	0.000228	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	3.01e-05	0.000226	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	2.99e-05	0.000224	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.99e-05	0.000224	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.97e-05	0.000223	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	2.96e-05	0.000222	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	2.96e-05	0.000222	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.96e-05	0.000222	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.96e-05	0.000222	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	2.95e-05	0.000221	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	2.93e-05	0.00022	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.92e-05	0.000219	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.91e-05	0.000219	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.91e-05	0.000219	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.86e-05	0.000214	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.78e-05	0.000208	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.74e-05	0.000205	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.72e-05	0.000204	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.69e-05	0.000202	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.69e-05	0.000202	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.68e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.68e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.67e-05	0.0002	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.65e-05	0.000199	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.64e-05	0.000198	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.64e-05	0.000198	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.62e-05	0.000197	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.62e-05	0.000197	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.59e-05	0.000194	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.59e-05	0.000194	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.59e-05	0.000194	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.57e-05	0.000193	CbGpPWpGaD
L-DOPA—DDC—Metabolism—COMT—attention deficit hyperactivity disorder	2.56e-05	0.000192	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	2.56e-05	0.000192	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.56e-05	0.000192	CbGpPWpGaD
L-DOPA—DDC—Metabolism—MAOA—attention deficit hyperactivity disorder	2.55e-05	0.000191	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.54e-05	0.000191	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.54e-05	0.00019	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.47e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.43e-05	0.000183	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.42e-05	0.000182	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.41e-05	0.000181	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.39e-05	0.00018	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.38e-05	0.000179	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.38e-05	0.000179	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	2.35e-05	0.000177	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.35e-05	0.000176	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.35e-05	0.000176	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	2.32e-05	0.000174	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.32e-05	0.000174	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.31e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	2.26e-05	0.000169	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	2.24e-05	0.000168	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.24e-05	0.000168	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.22e-05	0.000167	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.19e-05	0.000164	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.16e-05	0.000162	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.15e-05	0.000162	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.12e-05	0.000159	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.09e-05	0.000157	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.08e-05	0.000156	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.03e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.02e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.02e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.01e-05	0.000151	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.98e-05	0.000149	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	1.98e-05	0.000149	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.96e-05	0.000147	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.95e-05	0.000146	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.94e-05	0.000146	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.89e-05	0.000142	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.88e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.83e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.82e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.8e-05	0.000135	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.79e-05	0.000135	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.78e-05	0.000133	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.77e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.7e-05	0.000128	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.69e-05	0.000127	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.67e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.64e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.59e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.59e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.57e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.56e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.53e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.51e-05	0.000114	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.46e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.44e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.43e-05	0.000107	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.41e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.41e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.39e-05	0.000104	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.39e-05	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.37e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.37e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.36e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.29e-05	9.71e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.28e-05	9.58e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.28e-05	9.57e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.2e-05	9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.16e-05	8.69e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.12e-05	8.37e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—EP300—attention deficit hyperactivity disorder	1.1e-05	8.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.08e-05	8.11e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.06e-05	7.97e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.05e-05	7.87e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.01e-05	7.56e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	9.73e-06	7.31e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.73e-06	7.31e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	9.58e-06	7.19e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.06e-06	6.8e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.94e-06	6.71e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.9e-06	6.68e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.78e-06	5.84e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.41e-06	5.56e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.23e-06	5.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.84e-06	5.14e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	5.9e-06	4.43e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	5.86e-06	4.39e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.33e-06	4e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.8e-06	3.6e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.74e-06	3.56e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.63e-06	2.72e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	2.53e-06	1.9e-05	CbGpPWpGaD
